Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report)’s share price was up 3.2% during mid-day trading on Thursday. The company traded as high as $15.1850 and last traded at $15.04. Approximately 1,136,185 shares traded hands during trading, an increase of 2,020% from the average session volume of 53,591 shares. The stock had previously closed at $14.57.
Aerovate Therapeutics Stock Performance
The firm’s fifty day simple moving average is $16.07 and its 200 day simple moving average is $18.15. The stock has a market capitalization of $435.93 million, a P/E ratio of -5.03 and a beta of 0.95.
About Aerovate Therapeutics
Aerovate Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary arterial hypertension (PAH), a progressive disorder involving elevated blood pressure in the arteries of the lungs. The company was headquartered in Cambridge, Massachusetts, and its research programs were aimed at addressing the underlying vascular changes associated with pulmonary diseases.
Aerovate’s lead product candidate was AV-101, an inhaled dry-powder formulation of imatinib, a tyrosine kinase inhibitor.
Recommended Stories
- Five stocks we like better than Aerovate Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Aerovate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerovate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.jpg){kind=logo}
